Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 17/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418891 | 1.00 | NTRK1 (0.61) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL57129 | 0.85 | NTRK1 (0.58) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL57130 | 0.85 | NTRK1 (0.58) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL3126553 | 0.83 | NTRK1 (0.68) | NTRK1IGF1R | |
| SCHEMBL4299264 | 0.83 | NTRK1 (0.68) | NTRK1IGF1R | |
| SCHEMBL27872716 | 0.83 | NTRK1 (0.70) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL3425036 | 0.83 | NTRK1 (0.70) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL4072757 | 0.82 | NTRK1 (0.74) | NTRK1IGF1R | |
| SCHEMBL4696527 | 0.82 | NTRK1 (0.57) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL4696529 | 0.82 | NTRK1 (0.57) | NTRK1JAK2JAK3IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164490-A1 | PYRAZOLYL DERIVATIVES WITH ANALGESIC ACTIVITY AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN. | AstraZeneca AB (SE) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008054292-A1 | PYRAZOLYL DERIVATIVES WITH ANALGESIC ACTIVITY AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN. | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |